ALNY FY 2015 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

FY 2015 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$41M-18.7% YoY

Gross Profit

$41M100.0% margin

Operating Income

-$296M-720.3% margin

Net Income

-$290M-705.8% margin

EPS (Diluted)

$-3.45

Cash Flow

Operating Cash Flow

-$189M

Free Cash Flow

-$202M

Stock-Based Comp.

$46M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$122M

Stockholders' Equity

$1.3B

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$41M	$51M	-18.7%
Gross Profit	$41M	$51M	-18.7%
Operating Income	-$296M	-$405M	+26.9%
Net Income	-$290M	-$360M	+19.5%